Investor Alert

Oct. 14, 2020, 8:39 a.m. EDT

There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand

At least four of the still investigational vaccines have moved into Phase 3 clinical trials

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Getty Images

The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.

There are dozens of coronavirus vaccines in development, primarily in the preclinical phase when they are tested on animals. In the U.S., there are seven vaccine candidates that have moved into clinical trials with human participants, including four that have moved into the crucial Phase 3 development phase.

Read: Here’s what you need to know about clinical trials as drug makers push forward with coronavirus vaccine studies

The first and second phases of clinical studies are primarily conducted to test for safety, while the third and final stage is used to determine whether vaccines are efficacious and can prevent infection among participants. At that point, the vaccine makers will decide when to pursue an emergency-use authorization from the Food and Drug Administration and/or a full approval. The majority of the vaccines in development have received funding from the U.S. government, either to help support clinical development or pay for manufacturing and distribution of the vaccines as part of the Trump administration’s “Operation Warp Speed” program.

MarketWatch will update this tally as the vaccines move through development.

Vaccines in Phase 3 trials in the U.S. (cited in alphabetical order, by company name):

• AstraZeneca  , in partnership with the University of Oxford

Year-to-date stock performance: Up 7.8%.

Name: AZD1222.

Type: Vector-based.

Phase 1/2: Data from the Phase 1/2 trial, which is being conducted in the U.K., was published July 20 in the Lancet . It reported neutralizing antibody responses in 91% of 35 patients when using one test and 100% of 35 patients when using a different test.

Phase 3: This trial, which will be held in the U.S., is expected to enroll up to 30,000 participants. (Late-stage studies are also being conducted in Brazil, South Africa and the U.K.) Data are expected by the end of the year. However, trials were halted in early September over concerns about a serious adverse event; the U.K. trial was restarted but the U.S. trial has not yet resumed. This is the trial protocol .

Target effectiveness: 50%

Clinical development and manufacturing funding from the U.S. government: up to $1.2 billion.

U.S. dose promise: 300 million doses.

Dosing: 2 doses.

• BioNTech  and Pfizer Inc.  

Year-to-date stock performances: BioNTech, up 75%; Pfizer, down 8.3%.

Name: BNT162b2.

Type: mRNA.

Phase 1: The companies published preliminary data on July 1 for BNT162b1 as a preprint. They said then that 24 participants in the study who received two doses of the lower-dose vaccine developed neutralizing antibodies. A second preprint was published on Aug. 28 for BNT162b2 that found this candidate produced similar levels of antibodies but participants reported fewer reactions.

Phase 2/3: This trial is expected to focus on BNT162b2. It is expected to enroll up to 30,000 participants in Argentina, Brazil and the U.S. This is the trial protocol .

Target effectiveness: 60%

Manufacturing funding from the U.S. government: $1.95 billion.

U.S. dose promise: 100 million doses, with option to buy up to 500 million more doses.

Dosing: 2 doses.

• Johnson & Johnson  

Year-to-date stock performance: Up 1.2%.

Name: Ad26. COV2. S or JNJ-78436735

Type: Vector-based.

Phase 1/2a: The study began in the second half of July. J&J said Sept. 23 that the vaccine candidate demonstrated a “safety profile and immunogenicity after a single vaccination were supportive of further development” and preprint results would be published imminently.

Phase 3: It plans to enroll up to 60,000 people in the late-stage trial, which began dosing participants in September, in partnership with BARDA. This is the trial protocol . On Oct. 12, J&J confirmed that it had temporarily paused all trials for the vaccine, citing an “unexplained illness in a study participant.”

Target effectiveness: 60%.

R&D funding from BARDA: $456 million

1 2
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.